Compare InMode Ltd (INMD) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Stryker Corporation — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 131.2× InMode Ltd's market cap, and Stryker Corporation pays a 1.27% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Stryker Corporation for 21 Days on average.
| INMD | SYK | |
|---|---|---|
Market Cap | $809.93M | $106.24B |
Volume | 365,490 | 2,982,001 |
Sector | Health | Health |
52-Week High | $16.62 | $388.35 |
52-Week Low | $12.76 | $269.75 |
Typical Hold Time | 28 Days | 21 Days |
Enterprise Value | $313.27M | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent revenue around $370M. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical softness. Investment opportunity lies in potential acquisition premium and international growth, while risks include US sales decline and management capital allocation concerns. The stock faces near-term resistance at $14 with support at the same level.
Stryker (SYK) trades at $276.97, up 0.57% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 64.98% gross margins and 14.43% net income margin, though recent Q1 2026 earnings missed expectations. Analyst consensus remains strongly bullish with 71% buy ratings and $368.11 price target, representing 33% upside potential. Recent news highlights ongoing legal investigations regarding manufacturing issues that caused an 8.8% stock drop in September 2026.
SYK presents a compelling investment case with robust fundamentals and strong analyst support, though near-term headwinds from legal scrutiny and manufacturing challenges create uncertainty. The stock's current valuation at 28.7 P/E appears reasonable given growth prospects, but investors should monitor Q3 2026 earnings results on October 29 for confirmation of business recovery from recent setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
